Application 212364
- Type
- ANDA
- Sponsor
- ANNORA PHARMA
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | EMPAGLIFLOZIN; LINAGLIPTIN | EMPAGLIFLOZIN;LINAGLIPTIN | UNKNOWN | UNKNOWN | No | No |
| 002 | EMPAGLIFLOZIN; LINAGLIPTIN | EMPAGLIFLOZIN;LINAGLIPTIN | TABLET;ORAL | 25MG; 5MG | No | No |
Source provenance: Browse the complete Orange Book source catalog.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
Document, Submission type, Date table| Document | Submission type | Date |
|---|
| 67041 | ORIG | 2021-04-13 |